Gland Pharma Limited Stock

Equities

GLAND

INE068V01023

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:52 2024-05-31 am EDT 5-day change 1st Jan Change
1,840 INR -0.54% Intraday chart for Gland Pharma Limited -2.43% -4.38%
Sales 2024 56.65B 679M Sales 2025 * 64B 767M Capitalization 303B 3.63B
Net income 2024 7.72B 92.62M Net income 2025 * 9.53B 114M EV / Sales 2024 5.37 x
Net cash position 2024 * 25.38B 304M Net cash position 2025 * 18.45B 221M EV / Sales 2025 * 4.45 x
P/E ratio 2024
39.4 x
P/E ratio 2025 *
31.8 x
Employees 4,585
Yield 2024 *
0.13%
Yield 2025 *
-
Free-Float 38.38%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.54%
1 week-2.43%
1 month+7.54%
3 months+2.94%
6 months+1.70%
Current year-4.38%
More quotes
1 week
1 810.00
Extreme 1810
1 897.00
1 month
1 661.25
Extreme 1661.25
1 989.90
Current year
1 661.25
Extreme 1661.25
2 194.00
1 year
925.10
Extreme 925.1
2 194.00
3 years
861.00
Extreme 861
4 350.00
5 years
861.00
Extreme 861
4 350.00
10 years
861.00
Extreme 861
4 350.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 99-12-31
Director of Finance/CFO - 19-09-29
Chief Tech/Sci/R&D Officer - 97-12-31
Members of the board TitleAgeSince
Director/Board Member 54 22-03-09
Chief Executive Officer 55 99-12-31
Chairman 69 19-06-09
More insiders
Date Price Change Volume
24-05-31 1,840 -0.54% 192,335
24-05-30 1,850 -0.58% 268,605
24-05-29 1,861 +2.56% 196,219
24-05-28 1,815 -2.77% 151,435
24-05-27 1,866 -1.03% 747,213

Delayed Quote NSE India S.E., May 31, 2024 at 07:43 am EDT

More quotes
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
1,840 INR
Average target price
1,834 INR
Spread / Average Target
-0.31%
Consensus